Multiple System Atrophy Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Multiple System Atrophy pipeline constitutes 22+ key companies continuously working towards developing 24+ Multiple System Atrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Multiple System Atrophy Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple System Atrophy Market.

The Multiple System Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details

Some of the key takeaways from the Multiple System Atrophy Pipeline Report: https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav
• Companies across the globe are diligently working toward developing novel Multiple System Atrophy treatment therapies with a considerable amount of success over the years.
• Multiple System Atrophy companies working in the treatment market are Teva Pharmaceutical/MODAG GmBH, H. Lundbeck A/S/Genmab, Alterity Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others, are developing therapies for the Multiple System Atrophy treatment
• Emerging Multiple System Atrophy therapies in the different phases of clinical trials are- Emrusolmin (TEV-56286, Anle-138b), Amlenetug (Lu AF82422), ATH434-201/-202, Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, Verdiperstat, TAK-341, KM-819, rasagiline mesylate, Safinamide Methanesulfonate, AZD3241, NBMI, hOMSC300, DaTSCANTM Ioflupane, Droxidopa, and others are expected to have a significant impact on the Multiple System Atrophy market in the coming years.
• In July 2026, Dasher Neuroscience Holdings Inc. (TPEx: 7829), an AI-driven biopharmaceutical company specializing in central nervous system (CNS) drug discovery and development, has announced the successful completion of patient enrollment in its global, multicenter Phase II clinical trial evaluating YA-101 for the treatment of Multiple System Atrophy (MSA). The company expects to report top-line trial results in the first quarter of 2027. Simultaneously, Dasher Neuroscience is advancing discussions for global out-licensing partnerships and preparing for a global multicenter Phase III trial to accelerate the development and commercialization of YA-101 as a potential first-in-class therapy for MSA.
• In July 2026, Alterity Therapeutics Ltd (ASX: ATH) has received official meeting minutes from the U.S. Food and Drug Administration (FDA) confirming the regulatory pathway for ATH434, its lead investigational therapy for Multiple System Atrophy (MSA). The minutes reaffirm the outcomes of the previously announced End-of-Phase II meeting and provide additional guidance on the planned Phase III clinical trial. Notably, the FDA agreed that a single pivotal Phase III study, supported by confirmatory evidence, could be sufficient to support regulatory approval of ATH434 for the treatment of MSA.
• In March 2026, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on developing disease-modifying therapies for neurodegenerative disorders, announced that it has received favorable regulatory feedback from the U.S. Food and Drug Administration (FDA) after a Type C meeting. The discussion centered on the company's planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA).
• In November 2025, Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE), a biotechnology company focused on developing disease-modifying therapies for neurodegenerative disorders, announced that findings on baseline characteristics related to orthostatic hypotension (OH) from its ATH434-201 randomized, double-blind Phase 2 trial in Multiple System Atrophy (MSA) were highlighted in an oral presentation at the American Autonomic Society's (AAS) 36th International Symposium on the Autonomic Nervous System, held in Clearwater Beach, Florida, USA.
• In August 2025, The US Food and Drug Administration (FDA) has cleared Tiziana Life Sciences' investigational new drug (IND) application to proceed with its Phase IIa trial evaluating intranasal foralumab for the treatment of multiple system atrophy (MSA). The six-month, open-label study will examine the therapy's effects on clinical outcomes, microglial activation, and overall safety. Foralumab, a fully human anti-CD3 monoclonal antibody administered via nasal spray, will be delivered across eight three-week dosing cycles and is designed to address T cell-driven neuroinflammation.
• In February 2025, ATH434 by Alterity Therapeutics exhibited encouraging Phase 2 results in a randomized, double-blind trial for early-stage multiple system atrophy (MSA). The treatment, especially at a 50 mg dose, was well-tolerated and showed both clinical improvements and biomarker-based benefits.

Multiple System Atrophy Overview
Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder that affects multiple systems in the body.

Get a Free Sample PDF Report to know more about Multiple System Atrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Emerging Multiple System Atrophy Drugs Under Different Phases of Clinical Development Include:
• Emrusolmin (TEV-56286, Anle-138b): Teva Pharmaceutical/MODAG GmBH
• Amlenetug (Lu AF82422): H. Lundbeck A/S/Genmab
• ATH434-201/-202: Alterity Therapeutics
• Lu AF82422: H Lundbeck A/S
• Ampreloxetine (TD-9855): Theravance Biopharma
• AAV2-GDNF Gene Therapy: Brain Neurotherapy Bio, Inc
• ION464: Ionis Pharmaceuticals, Inc.
• ATH434: Alterity Therapeutics
• Verdiperstat: Biohaven Pharmaceuticals, Inc.
• TAK-341: Takeda
• KM-819: Kainos Medicine Inc.
• rasagiline mesylate: Teva Branded Pharma
• Safinamide Methanesulfonate: Zambon SpA
• AZD3241: AstraZeneca
• NBMI: EmeraMed
• hOMSC300: Cytora Ltd.
• DaTSCANTM Ioflupane: GE Healthcare
• Droxidopa: Chelsea Therapeutics

Multiple System Atrophy Route of Administration
Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Multiple System Atrophy Molecule Type
Multiple System Atrophy Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Multiple System Atrophy Pipeline Therapeutics Assessment
• Multiple System Atrophy Assessment by Product Type
• Multiple System Atrophy By Stage and Product Type
• Multiple System Atrophy Assessment by Route of Administration
• Multiple System Atrophy By Stage and Route of Administration
• Multiple System Atrophy Assessment by Molecule Type
• Multiple System Atrophy by Stage and Molecule Type

DelveInsight's Multiple System Atrophy Report covers around 24+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Multiple System Atrophy product details are provided in the report. Download the Multiple System Atrophy pipeline report to learn more about the emerging Multiple System Atrophy therapies
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key companies in the Multiple System Atrophy Therapeutics Market include:
Key companies developing therapies for Multiple System Atrophy are - Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others.

Multiple System Atrophy Pipeline Analysis:
The Multiple System Atrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment.
• Multiple System Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Multiple System Atrophy drugs and therapies
https://www.delveinsight.com/sample-request/multiple-system-atrophy-msa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Multiple System Atrophy Pipeline Market Drivers
• Increased Awareness and Diagnosis, rising Genetic Research Activities are some of the important factors that are fueling the Multiple System Atrophy Market.

Multiple System Atrophy Pipeline Market Barriers
• However, ethical and Practical Challenges in clinical trials, lack of Early and Specific Diagnostic Biomarkers, poor Understanding of Disease Mechanism and other factors are creating obstacles in the Multiple System Atrophy Market growth.

Scope of Multiple System Atrophy Pipeline Drug Insight
• Coverage: Global
• Key Multiple System Atrophy Companies: Teva Pharmaceutical/MODAG GmBH, H. Lundbeck A/S/Genmab, Alterity Therapeutics, Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others
• Key Multiple System Atrophy Therapies: Emrusolmin (TEV-56286, Anle-138b), Amlenetug (Lu AF82422), ATH434-201/-202, Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, Verdiperstat, TAK-341, KM-819, rasagiline mesylate, Safinamide Methanesulfonate, AZD3241, NBMI, hOMSC300, DaTSCANTM Ioflupane, Droxidopa, and others
• Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies
• Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.